SYRESpyre Therapeutics
About Spyre Therapeutics
Spyre Therapeutics (NASDAQ:SPYR) focuses on advancing healthcare through innovative drug development and therapies with the aim to significantly improve patient outcomes in various disease areas. It leverages cutting-edge research and development practices to create a pipeline of promising treatments. With a commitment to excellence and patient health, Spyre Therapeutics tirelessly works on new projects to address unmet medical needs, aiming to bring revolutionary products to the market. Their objectives include not just commercial success, but also making lasting contributions to medicine and patient care globally.
What is SYRE known for?
Snapshot
Public US
Ownership
2013
Year founded
30
Employees
Massachusetts, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of Spyre Therapeutics
- Development of precision oncology drugs targeting specific genetic mutations in cancer cells.
- Research into novel small molecule inhibitors for the treatment of hard-to-target cancers.
- Collaboration on biomarker-driven clinical trials aiming to optimize patient outcomes.
- Creation of a proprietary drug discovery platform enhancing the identification and development of anticancer agents.
- Investigation into combination therapies that leverage the immune system for cancer treatment.
- Expansion of a diagnostic toolkit to better match patients with effective treatments based on their genetic profile.
Spyre Therapeutics executive team
- Dr. Cameron Turtle DPHIL, Ph.D.CEO & Director
- Mr. Scott L. BurrowsChief Financial Officer
- Dr. Sheldon Sloan M.B.E., M.D.Chief Medical Officer
- Dr. Janet Gunzner-Toste M.B.A., Ph.D.Senior Vice President of Operations
- Mr. Brian ConnollyChief Technical Officer
- Mr. Eric McIntyreVice President of Finance & Investor Relations
- Ms. Heidy Abreu King-Jones J.D., L.L.M.Chief Legal Officer & Corporate Secretary
- Mr. James MyersVice President of Quality & Compliance
- Dr. Justin LaFountaine Ph.D.Senior Vice President of Corporate Development
- Ms. Melissa CooperSenior Vice President of People